Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
OHE Involved in Developing New AMS Report on Stratified Medicines
15 July 2013
Professor Adrian Towse, OHE’s Director, joined Professor Sir John Bell and Professor Andrew Morris at the Science Media Centre last week to launch Realising the Potential…
Forecasting the Challenges and Economics of Drug Development in 2022
9 July 2013
A new publication from the Office of Health Economics captures the views of thought leaders from around the world about the scientific and economic climate for…
Defining Innovation in Medicines and Transforming it into Value
3 July 2013
In June, OHE’s Jorge Mestre-Ferrandiz participated as a speaker at the Summer Course on the Evaluation of Medicines at the University of Alcalá in Spain. His…
Critical Factors Affecting Pharmaceutical R&D and the Availability of New Drugs
18 June 2013
Dr Jorge Mestre-Ferrandiz, OHE’s Director of Consulting, was a recent guest lecturer at Imperial College London. His comprehensive presentation covered the gamut of issues that influence…
OHE’s Towse on Challenges in Valuing Genomic Medicines
23 May 2013
In this video, Adrian Towse discusses the challenges and importance of appropriately valuing genomic medicine. He addresses both gene therapies and “pharmacogenomics” — those medicines that…
Valuing Co-Dependent Medical Technologies: Improving Methods and Processes
23 April 2013
Advances in science and technology are producing more and better means for diagnosing disease, matching patients to the best therapies, and tracking the progress of treatment.…
The Economics of the Market for Medicines: 2013 Review
26 March 2013
OHE’s Dr Jorge Mestre-Ferrandiz is a visiting lecturer in the Department of Economics at City University London. As part of his 2013 activities, he recently gave…
Reasons for Discontinuation of R&D Projects: Lead and Follow-on Indications
12 March 2013
The reasons for discontinuation of R&D projects in the biopharmaceutical industry are often a matter of conjecture. In a recent presentation to the 25th Annual EuroMeeting…
New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
31 January 2013
Just out in the International Journal of Technology Assessment in Health Care is an important new study that reviews appraisals of breast cancer and colorectal cancer…